At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Trading 12-11 14:53:48 EST
8.48
+0.64
+8.10%
High8.51Low7.98Vol4.11M
Open8.09D1 Closing7.84Amplitude6.76%
Mkt Cap2.91BTradable Cap1.96BTotal Shares342.83M
T/O34.03MT/O Rate1.78%Tradable Shares231.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  12-11 19:32
Nuvation Bio Is Maintained at Buy by HC Wainwright & Co.
Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $18 From $10
THOMSON REUTERS  ·  12-11 19:09
Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $18 From $10
Why Nuvation Bio (NUVB) Is Up 6.5% After Strong Safusidenib Phase 2 Glioma Data And What's Next
Simply Wall St.  ·  12-07
Why Nuvation Bio (NUVB) Is Up 6.5% After Strong Safusidenib Phase 2 Glioma Data And What's Next
Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List
THOMSON REUTERS  ·  12-07
Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List
Nuvation Bio Chief Medical Officer Dongfang Liu Reports Sale of Common Shares
Reuters  ·  12-04
Nuvation Bio Chief Medical Officer Dongfang Liu Reports Sale of Common Shares
BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
Reuters  ·  12-04
BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
Reuters  ·  12-03
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
BUZZ-Nuvation Bio rises on brain cancer drug data
Reuters  ·  12-03
BUZZ-Nuvation Bio rises on brain cancer drug data
Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma
Reuters  ·  12-03
Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 Idh1-Mutant Glioma in Neuro-Oncology
THOMSON REUTERS  ·  12-03
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 Idh1-Mutant Glioma in Neuro-Oncology
Nuvation Bio Inc. highlights pipeline progress and IBTROZI launch in oncology-focused corporate presentation
Reuters  ·  12-01
Nuvation Bio Inc. highlights pipeline progress and IBTROZI launch in oncology-focused corporate presentation
Nuvation Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-01
Nuvation Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB)
TIPRANKS  ·  11-30
Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB)
Nuvation Bio Executives to Join Fireside Chats at Major Healthcare Investor Conferences
Reuters  ·  11-27
Nuvation Bio Executives to Join Fireside Chats at Major Healthcare Investor Conferences
Nuvation Bio to discontinue development of NUV-1511
TIPRANKS  ·  11-27
Nuvation Bio to discontinue development of NUV-1511
Clear Street says thesis intact after Nuvation’s NUV-1511 discontinued
TIPRANKS  ·  11-27
Clear Street says thesis intact after Nuvation’s NUV-1511 discontinued
Nuvation Bio Inc - Discontinues Development of Nuv-1511 - SEC Filing
THOMSON REUTERS  ·  11-26
Nuvation Bio Inc - Discontinues Development of Nuv-1511 - SEC Filing
Nuvation Bio: Nuv-1511 Well Tolerated, Did Demonstrate Promising Signals in Some Patients
THOMSON REUTERS  ·  11-26
Nuvation Bio: Nuv-1511 Well Tolerated, Did Demonstrate Promising Signals in Some Patients
Nuvation Bio Inc: Co Has Made This Decision Due to Lack of Sufficiently Consistent Efficacy Across Cohorts
THOMSON REUTERS  ·  11-26
Nuvation Bio Inc: Co Has Made This Decision Due to Lack of Sufficiently Consistent Efficacy Across Cohorts
Nuvation Bio: Resources Budgeted for Nuv-1511 to Be Transferred to Other Pipeline Molecules & to Development of DDC Candidates
THOMSON REUTERS  ·  11-26
Nuvation Bio: Resources Budgeted for Nuv-1511 to Be Transferred to Other Pipeline Molecules & to Development of DDC Candidates

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--